Soleno Therapeutics, Inc. (SLNO)
May 18, 2026 - SLNO was delisted (reason: acquired by NBIX)
53.01
0.00 (0.00%)
Inactive · Last trade price on May 15, 2026

Company Description

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome.

The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.

Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.

Soleno Therapeutics, Inc.
Soleno Therapeutics logo
CountryUnited States
Founded1999
IPO DateNov 13, 2014
IndustryBiotechnology
SectorHealthcare
Employees182
CEOAnish Bhatnagar

Contact Details

Address:
100 Marine Parkway, Suite 400
Redwood City, California 94065
United States
Phone650 213 8444
Websitesoleno.life

Stock Details

Ticker SymbolSLNO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001484565
CUSIP Number834203200
ISIN NumberUS8342033094
Employer ID77-0523891
SIC Code2834

Key Executives

NamePosition
Dr. Anish Bhatnagar M.D.Chairman, President and Chief Executive Officer
James H. MacKanessExecutive Officer
Meredith Manning M.B.A.Chief Commercial Officer
Kevin Norrett M.B.A., M.S.Chief Business Officer
Dr. Manher A. Joshi M.D.Chief Development Officer
Jennifer FulkChief Financial Officer
Jesse SchumakerGeneral Counsel
Lauren BudesheimSenior Vice President of People
Kristen Yen M.S.Senior Vice President of Global Clinical Operations and Patient Advocacy
Dr. Neil M. Cowen M.B.A., Ph.D.Senior Vice President of New Product Planning

Latest SEC Filings

DateTypeTitle
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 18, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments